NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)

NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)

Key details

This NOFO was specifically for the NCORP Academic Community Sites component of NCI’s Community Oncology Research Program. Its FY 2027 application cycle has closed. NCI’s archive lists RFA-CA-27-008 as expired, and no subsequent round is announced in the official pages checked for this update. This page is an archive of the closed notice, not an invitation to submit now; applicants should wait for a newly published NOFO before relying on dates, amounts, or instructions for another cycle.

If you are an institution that already manages a network of community oncology providers, this opportunity is materially different from most NIH disease-focused R01-style grants. The goal here is not mainly to fund a single scientific question; it is to support an operational model that can sustain trial-related and other human-subjects oncology research in real-world care settings.

Why this opportunity is different from a standard NIH grant

Most NIH award systems reward a strong hypothesis and a polished scientific plan. This one also does that, but it places unusually high weight on organizational systems: governance, affiliate engagement, operational readiness, and sustainable accrual capacity.

The NOFO framed Academic Community Sites as consortia led by an academic hospital or clinic program that could coordinate multiple community partners. The policy objective was to bring rigorously conducted cancer studies into diverse care environments and increase representativeness of research participants.

What the program is trying to buy

The official intent is to support sites that can:

• sustain accrual to treatment, screening, cancer prevention, care-delivery, and quality-of-life studies,
• participate in and accrue patients to NCTN treatment trials, while applications themselves could not propose clinical trials,
• coordinate with affiliate/sub-affiliate sites,
• provide reliable data and operational quality across the network,
• build infrastructure and reporting capacity that allows ongoing, not one-off, research participation.

That means the strongest applications are those that show a networked system rather than a single research lab. An isolated institution with no clear affiliate pathways will be less competitive even if the science is strong.

Who this is built for (and who it is not)

Strong fit

The program is suitable for organizations that match all of these conditions:

1. They are U.S.-based and eligible under NIH participation rules.
2. They can serve as a real academic hub rather than a loose consortium on paper.
3. They can show leadership and governance that can manage multicenter oncology workflow, not just grant administration.
4. They can present a documented history of participation in relevant research and a realistic accrual plan for forthcoming years.
5. They can prepare and submit a full NIH application package in time, including all registrations and system requirements.

Officially included entity categories

According to the NOFO text, eligible organizations include a broad set: higher-education institutions, nonprofits, for-profits (including small businesses), local and federal governments, and some additional entities such as regional organizations and tribal organizations (with details and caveats in the full NOFO).

What is important for planning is that this is a site capacity program. The program explicitly expects an academic hospital/clinic structure with clinical care, training, and research integration.

Not eligible

The FY 2027 NOFO explicitly excluded some major categories even if they appear adjacent to healthcare:

• Non-domestic entities are not eligible.
• Foreign components of U.S. organizations are not allowed.
• VA hospitals and military treatment facilities cannot be the lead applicant, though they may be affiliates if they are not the primary accrual source.
• An institution that is an awardee or an affiliate of an NCTN Lead Academic Participating Site funded by NCI’s Division of Cancer Treatment and Diagnosis is excluded from applying under this NOFO.

For a future cycle, institutions uncertain about a relationship should check that cycle’s eligibility language and consult its listed NIH contacts before preparing an application.

The closed FY 2027 cycle: dates and status

These are the dates published for the now-closed FY 2027 cycle. They are preserved for reference and are not future application dates:

• Posted: May 21, 2026
• Open date: August 18, 2026
• Application due: September 18, 2026 (local time, 5:00 PM)
• Expiration: September 19, 2026. NCI’s archive now lists this announcement as expired.
• Scientific review pipeline and anticipated award timing is shown in the NOFO as March/May/July 2027 windows (aligned with review/advisory cycle expectations).

A practical lesson from the closed cycle is that this was not a last-minute sprint opportunity. The notice said registrations could take six weeks or more and that incomplete registration was not a valid reason for late submission. No late applications were accepted. No next application window is stated in the official pages reviewed; the prior cycle dates should not be carried forward as estimates.

How the FY 2027 application was submitted (historical guidance)

For the closed cycle, applications used the NIH SF424(R&R) process rather than a short-form application. These instructions describe that notice only. They do not provide a route to apply after the deadline, and a future cycle may change its requirements.

Non-negotiables

• Applicant organization registrations had to be complete before submission.
• SAM registration current and complete.
• eRA Commons account for all PD(s)/PI(s) and ORCID linkage.
• Applications had to be submitted electronically; the notice offered NIH ASSIST, an institutional system-to-system route, or Grants.gov Workspace, with eRA Commons used to track applications for the latter routes.
• Applications must be fully compliant with NIH “How to Apply” rules and section-specific NOFO instructions.

The notice stated registrations could take six weeks or more and warned that late registrations were not valid reasons for late submission. For historical context, an applicant in that cycle would have needed to:

• Set up registrations first.
• Use ASSIST/Grants.gov Workspace only after institutional signoff on profile and PI account details.
• Pre-validate components in eRA Commons.
• Budget and narrative should be built in parallel and updated with accrual projections only after confirming affiliate commitments.

Submission mechanics

The notice listed these submission options:

• ASSIST,
• institutional system-to-system pathways,
• Grants.gov Workspace.

Applicants could use their institution’s system-to-system route if available, NIH ASSIST, or Grants.gov Workspace. The notice required compliance with both the NIH Research (R) Application Guide and its program-specific instructions.

The notice encouraged early submission so errors could be corrected before the deadline and stated that no late applications would be accepted. Because the deadline has passed, corrections or new submissions cannot now be made under this cycle.

What the FY 2027 application had to prove

The review process starts at compliance, then moves into merit criteria. If your administrative sections are weak, the science is not scored.

Section-level expectations

The NOFO’s structure points applicants to three practical expectations:

1. Operational design: Who runs the hub, governance and reporting roles, and how leadership aligns with research programs.
2. Community and affiliate architecture: How Primary/ Sub-affiliates are organized, what each contributes, and whether that network can activate and support studies.
3. Accrual systems: Evidence of realistic patient flow and ability to meet required accrual targets across cancer control, prevention, screening/surveillance, treatment, and imaging-focused research activity.

Accrual and budget logic in plain language

This NOFO does not force a fixed award cap in the application instructions. It does set a program-level cap and intended funds. Budgets are expected to reflect:

• projected annual accrual,
• infrastructure needed to support affiliate and main-site coordination,
• realistic overhead and support costs.

For the FY 2027 cycle, the application was expected to include per-case cost logic and required supporting documents showing then-current and planned operations. In plain English, reviewers wanted to know whether a team could convert its network design into enrolled participants and high-quality data.

Attachments and evidence stack

The application requires multiple attachments and detailed tables. The NOFO references sections covering:

• accrual records for NCTN trials over a defined date window,
• committee participation and leadership history,
• activation timelines for trials at affiliate sites,
• facilities and resources documentation,
• governance and staffing readiness.

The practical lesson for a future announcement is that this kind of evidence takes advance coordination. For the closed cycle, teams needed to assemble items such as:

• clear affiliate list and role mapping,
• prior accrual and operations history,
• staffing plan with responsibilities,
• timeline realism with contingencies.

Review logic in the FY 2027 notice

NIH review for this NOFO includes:

• scientific and technical merit,
• relevance to program priorities,
• availability of funds and geographic balance,
• peer review and advisory council stages.

Because this is a competitive cohort-wide mechanism across both community and academic community site components, score ranking relative to other high-quality applications matters. The NOFO indicates only a subset may be discussed and assigned high-level scores. This is standard for NIH but especially meaningful here because awards are capped by both quality and allocation geography.

Common review traps:

• Missing evidence of measurable affiliate-level operational support,
• treating “patient access” and “accrual readiness” as narrative claims without operational detail,
• weak human subjects compliance sections,
• underbuilt budget narrative with no accrual justification,
• incomplete registration and Commons credentials.

Common mistakes and practical failure modes

Mistake 1: Underestimating registration time

Registration timing was a material risk in this NOFO. The notice warned that registrations could take six weeks or more and said incomplete registration was not a valid reason for a late submission; it did not accept late applications.

Mistake 2: Submitting a science-first proposal without a systems-first execution plan

Even excellent investigators lose when they do not explain how trials are activated, monitored, and operationalized across affiliate sites. The program needs implementation capacity evidence, not just promising concepts.

Mistake 3: Mismatched scope

The NOFO explicitly says clinical trials are not allowed. Some teams overbuild a trial protocol style application and then have to repurpose late. The right framing is community infrastructure and research support capacity in an NIH network context.

Mistake 4: Weak catchment and feasibility claims

Reviewers look for evidence that your catchment area and affiliate network support the stated accrual goals. Overbroad claims with limited proof are interpreted as strategic risk.

Mistake 5: Not budgeting for travel and coordination needs

Even if budgets are flexible in principle, NCORP activity implies collaboration costs and data coordination overhead. Ignoring these may be seen as underplanned and reduce score on feasibility.

Preparation sequence used for the closed cycle

The sequence below explains the planning assumptions that fit the published dates. It is retained for teams documenting the past cycle; it is not a forecast or schedule for a future round.

T-minus 8 to 10 weeks (before the 2026 opening)

• Confirm eligibility path and exclusion checks.
• Lock internal lead structure.
• Start registrations immediately if not already active.
• Identify all primary/sub-affiliates and confirm letters/agreements.

T-minus 6 to 4 weeks (after the 2026 opening)

• Draft Organizational overview with governance map.
• Validate historical accrual data and produce a clean baseline table.
• Design required attachments and page-limit compliance map.

T-minus 3 to 1 week (submission build)

• Upload draft in SF424(R&R).
• Run full compliance checks against NIH instructions and NOFO-specific appendices.
• Pre-submit internally in the grants office for technical validation.

Final week

• Finalize budgets from accrual model and support costs.
• Check all signatures, registration status, and PD/PI Commons linkage.
• Submit early when possible to permit corrections.

FAQ for applicants

Does this have a fixed grant amount per award?

No fixed single-award cap is stated in the NOFO summary. The page specifies that NIH intended to commit $73M in FY 2027 across Community and Academic Community Sites.

Can a large cancer center apply directly?

Only if it meets the specific definition used in this NOFO for an academic hospital/clinic program and is eligible under NIH organization rules. The NOFO also calls out exclusions (for example, certain NCI lead-site relationships).

Can this be run by a commercial company?

For-profit entities are listed in general eligibility categories, but this is still fundamentally a health system/academic-affiliate model. Commercial organizations should assess fit carefully against the governance and care-delivery requirements.

Can this accept foreign collaborators?

Non-domestic entities are excluded as applicants and foreign components are not allowed.

When is no-application status most risky?

If registrations are incomplete, required attachments are missing, or if the application package violates NIH formatting/compliance details. In this NOFO, technical non-compliance is usually terminal.

Official references and support points

Use the NOFO and NIH systems pages as your authoritative source base, especially for final instructions and any updates:

• Official NOFO PDF page: https://files.simpler.grants.gov/opportunities/e749b186-9043-4eb2-9288-4833ede537f7/attachments/4c389a46-f2d7-4527-90c6-e0945b90ec68/RFA-CA-27-008-Full-Announcement.html
• NIH Grants & Funding overview pages linked from the NOFO
• grants.gov Workspace
• eRA Commons
• ORCID linkage guidance
• NIH Grants Policy and peer review references listed in the NOFO

If your team is serious about competing, the fastest way to improve outcomes is to run a structured “compliance and readiness preflight” first, before finalizing scientific narrative. This NOFO rewards institutions that can prove capability to run a sustained, multi-site, network-ready research model across cancer care settings.